Efficacy and tolerability of a nutraceutical combination of red yeast rice, guggulipid, and chromium picolinate evaluated in a randomized, placebo-controlled, double-blind study.
In this study, a randomized, placebo-controlled, double-blind study which consisted of 4 weeks run-in period and 8 weeks treatment period was performed. Based on the study results, NutraforChol® effectively decreased total cholesterol (-15.9 %) and LDL level (-19.9 %) after two weeks consumption. The total cholesterol and LDL reduction were maintained during 8 weeks study period. At study termination (week 8), there was a significant difference between total cholesterol level of NutraforChol® treated group (173.5 ± 21.7 mg/dL) and placebo-treated group (204.5 ± 22.8 mg/dL) (p < 0.05). In addition, there was a significant difference between LDL level at week 8 in NutraforChol® group (115.5 ± 22.2 mg/dL) and placebo-treated group (145.1 ± 23.7 mg/dL) (p < 0.05). The tolerability of NutraforChol® was also evaluated. There were no significant changes (p > 0.05) on renal and liver function parameters between baseline and study termination. Thus, NutraforChol® may be considered as a complementary or alternative safe nutraceuticals for the treatment of mild dyslipidemic subjects.
PMID: 31987238 [PubMed - in process]
Source: Complementary Therapies in Medicine - Category: Complementary Medicine Authors: Iskandar I, Harahap Y, Wijayanti TR, Sandra M, Prasaja B, Cahyaningsih P Tags: Complement Ther Med Source Type: research
More News: Alternative and Complementary Therapies | Cardiology | Chemistry | Cholesterol | Chromium | Complementary Medicine | Coronary Heart Disease | Heart | Heart Disease | Liver | Red Yeast Rice | Statin Therapy | Study | Urology & Nephrology